Betsy Beasley is a finance, human resources and administration professional who has helped establish and grow more than 10 startup medical companies in the past 16 years. Her first venture in the world of medical and pharmaceutical products was with FoxHollow Technologies, which went public in 2004. Prior to joining Allay, Betsy teamed up with the Foundry and ForSight partners from 2005 to 2014 to drive the growth and several successful exits for companies started both at The Foundry and in ForSight Labs, an incubator focused on developing and applying solutions to improve the sight, care and quality of life of visually impaired patients.

Betsy is a San Francisco Bay Area native and holds a BS in Finance from Santa Clara University.

Heather Berns has served as vice president, clinical operations at Allay Therapeutics since September 2023. She is a global clinical operations leader with over 25 years of experience spanning all phases (I – IV) of clinical development across a spectrum of therapy areas including infectious disease (HIV, HBV, HCV, influenza), cardiovascular disease, rare disease, renal impairment and CNS disorders.

Prior to Allay, Heather led the clinical operations teams at Assembly Biosciences and Resverlogix. She also brings to Allay valuable experience gained in the early development group at Roche in addition to experience in the CRO and lab services industries. Heather earned a master’s degree in microbiology from the University of Texas at Austin and a bachelor’s degree in biology from the University of California at Santa Cruz.

Adam Gridley has served as chief executive officer at Allay Therapeutics since November 2020. He has over 25 years’ experience in the biotechnology, medical device and pharmaceutical industries leading venture capital-backed startups to mature, fully integrated commercial organizations.

Prior to Allay, Adam was the CEO of Entera Bio (NASDAQ: ENTX), a biotechnology company specializing in the oral delivery of large molecules and biologics, as well as the president and CEO of Histogenics (NASDAQ:HSGX), a cell therapy and biologics company developing novel therapeutics for cartilage defects, where he led a completed IPO, multiple fundraisings and strategic transactions. Prior to Histogenics, Adam was senior vice president, technical operations and global site head at Merz Pharma.  He was also previously senior vice president of corporate development at BioForm Medical (NASDAQ: BFRM) prior to the company’s sale to Merz, where he played a key role in an IPO as well as acquisitions and product launches. Adam was previously on the board of directors of the Alliance for Regenerative Medicine and is on the board of advisors for Life Science Cares.  He also serves as the executive chairman of LifeSprout, a Johns Hopkins founded company developing aesthetic and regenerative medicine products. Adam holds a bachelor’s degree and MBA from the University of Denver.

Sharon Hall has served as senior vice president, regulatory at Allay Therapeutics since December 2022, after originally joining Allay in April 2021.  She brings nearly 30 years’ experience in pharmaceuticals and biotech regulatory affairs, during which time she has successfully overseen submission for multiple NDAs, MAAs, INDs and FDA audits.

Prior to Allay, she was an independent consultant for various pharmaceutical companies and vice president, regulatory affairs at Revance Therapeutics (NASDAQ: RVNC), a biotech focused on innovative aesthetic and therapeutic offerings. Sharon has served in director-level positions at multiple drug delivery and pharmaceutical companies including Pharmacofore and Connetics and Aerogen. She holds bachelor’s degrees in biology and psychology from the University of Texas at San Antonio.

David Hewitt has served as chief medical officer at Allay Therapeutics since July 2021. He is a neurologist with a successful career in pharmaceutical clinical development spanning two decades.

Prior to Allay, David was senior vice president, clinical development at Nura Bio. David joined Nura Bio from Karuna Therapeutics, where he served as senior vice president of clinical development. Previously, he was vice president of neuroscience and pain at Syneos Health.  He also served in the neurology group at Merck, where he led the pediatric program for the treatment of migraine and the successful pediatric filing for Maxalt and worked on the BACE program for the treatment of prodromal Alzheimer’s disease. David began his career in biopharma at the Ortho-McNeil division of Johnson & Johnson, where he designed and conducted clinical trials in acute and chronic pain and migraine. He also worked on a large postoperative pain program that led to the approval of the drug device system Ionsys.

David earned his MD at the University of Rochester School of Medicine, served a residency at New York Hospital Cornell Medical Center and then a fellowship in pain, palliative care and analgesic research at Memorial Sloan-Kettering Cancer Center. He then spent six years at Emory University leading its pain and headache clinic and conducting industry-based clinical trials.

Kristen Howells joined as VP Finance, Corporate Controller at Allay Therapeutics in December 2022.  She brings over 15 years of experience in technical and operational accounting with emphasis in process creation, system implementation, control documentation and building out accounting teams for growth organizations.

Prior to Allay, Kristen served as vice president, finance at ESCAPE Bio, a pharmaceutical company focused on neurodegenerative diseases.  Before that she held various roles in finance as well as Chief of Staff at Accuray, a medical device company in the oncology space, and started her career as an auditor with Grant Thornton LLP.

She holds a bachelor’s degree in business administration with a concentration in accounting from Sonoma State University and holds a CPA license in the state of California.

Cyndi Lee has served as vice president, product development at Allay Therapeutics since September 2020, having joined as senior director of program management in August 2019. She brings over 15 years of experience in medical device and biotech product development, manufacturing and supply chain management and business operations.

Prior to Allay, Cyndi served as director of program management for start-up medical device companies Neuspera Medical and Topera (Abbott Electrophysiology after its acquisition), where she developed cutting-edge technologies for neuromodulation and electrophysiology diagnostics, respectively. Her broad experience in those roles included program management; research and development; manufacturing operations; directing cross-functional product development teams; and building infrastructure and processes to support commercialization within the startup environment to integrate into a multi-national organization. Earlier in her career, Cyndi held various roles in product development and program management at Johnson & Johnson and Medtronic. Cyndi holds a bachelor’s degree in bioengineering from the University of California Berkeley, a master’s degree and Ph.D. in mechanical engineering from the Massachusetts Institute of Technology and completed a post-doctoral fellowship at the AO Institute in Davos, Switzerland.

Hans Schulz has served as vice president, quality at Allay Therapeutics since May 2019. He brings over 20 years’ experience ensuring the efficacy and safety of devices and treatments while keeping the production process as efficient as possible.

Prior to Allay, Hans served as vice president, quality at Intersect ENT, a drug-device combination product company specializing in advancing treatment of ear, nose and throat conditions. Earlier in his career, Hans developed quality engineering best-practices at multiple medical device and biotechnology firms in the United States, including Pulmonx and FoxHollow. He holds a bachelor’s degree in applied economics from the University of San Francisco.

Koon Kiat Teu (KK) has served as vice president and general manager, Singapore at Allay Therapeutics since December 2022 and originally joined Allay in February 2018. KK brings nearly 15 years of research and development experience in medical device and biotech products, bringing to market various products in multiple applications.

KK was general manager of Orchid Medical prior to Allay’s acquisition of the company in 2018. He also served as research and development director of Singapore startup, JN Medsys Pte Ltd, where he was a part of the company since its early phase and played key roles through the design and development cycle of its first commercial machine, Clarity^TM.  KK ensured key development milestones were met, enabling the company to successfully secure various rounds of government funding and external investments. Earlier in his career, KK held roles of increasing responsibility in research and development at Biosensors Interventional Technologies Pte Ltd, an interventional cardiology device company, where he was involved in several product development projects and led product transfer projects between Singapore, the U.S. and China. KK holds a bachelor’s degree in mechanical engineering from National University of Singapore and a master’s degree in mechanical engineering from Nanyang Technological University.

Mike is a general partner at Lightstone Ventures, where he focuses on investments in the biopharmaceutical and medical device industries. Earlier in his career, Mike served as a director of business development for Inhale Therapeutic Systems (now Nektar Therapeutics), a venture-backed pulmonary drug delivery company, where he led partnering activities with a number of pharmaceutical and biotechnology companies internationally. Mike was also a principal at The Wilkerson Group and currently serves as an adjunct professor at the Tuck School of Business Administration at Dartmouth College. Mike sat on the board of directors for the National Venture Capital Association and remains active in helping to shape policy affecting both innovation and healthcare. Mike holds a bachelor’s degree in mechanical engineering from Lehigh University and an MBA from the Tuck School of Business.

Mark has been an operating partner of Lightstone Ventures since 2013, where he advises the medical device team with deal sourcing, due diligence, and portfolio company management. Mark is also a co-founder of The Foundry, LLC, the premier medical device company incubator that has founded and financed over twenty new medical device companies. Prior to that role, Mark served as a co-founder and consulting director of research and development for Ventrica, Inc. Previously, Mark was a senior member of the research and development team at Medtronic Micro Interventional Systems. He has spent over thirty years in the design, testing and manufacture of medical devices. Mark also serves in governance or advisory roles for several other medical device innovators, including as chairman for FIRE1, as a director for Half Moon Medical and as a board observer for Nuvaira and Shoulder Innovations. Mark holds a bachelor’s degree in biomedical engineering from Boston University.

Tiffany is currently a Principal at NEA and invests in life sciences, with a focus on medtech, healthtech, and innovations that sit at the intersection of technology and medicine. She currently serves as a Board Director for Allay Therapeutics, FIRE1, Magenta Medical, and the ExploraMed incubator, and also works with Revelle Aesthetics, Moximed, Setpoint Medical, and Willow. She previously served on the Board of Relievant. Tiffany has had a decade-long career in healthcare investments and consulting, with prior roles at Kaiser Permanente Ventures and L.E.K. Consulting. She received a BA in Business Economic Theory from UCLA and an MBA from Harvard Business School.

J.C. is a Principal on NEA’s healthcare team, focused on life sciences investments—particularly in biopharma. Before joining NEA in 2020, J.C. led Global Search and Evaluation for Neuroscience, Ophthalmology, and Rare Diseases at Genentech and Roche. He received a BS in biological sciences from Stanford University, an MD from the Perelman School of Medicine at the University of Pennsylvania, and an MBA from The Wharton School, where he was a Joseph Wharton Fellow.

Paul oversees Arboretum’s investment process and leads the firm’s operations. His portfolio investments focus on capital-efficient health IT and service companies applying technology to underserved markets. Paul currently serves as a board director for BioIQ,  VYDENCE Medical,  and Delphinus Medical and is the former Chief Operating Officer for CerviLenz (now Lucina), where he led the design of the company’s first commercial product from concept to launch. Prior to joining Arboretum, Paul worked at Ford Motor Company holding management positions within product development, manufacturing, and business strategy. He currently serves on the National Advisory Board for the Institute for Healthcare Policy & Innovation at the University of Michigan. Paul earned a BS and MS in Mechanical Engineering from the University of Michigan and an MBA from the Ross School of Business at the University of Michigan.

Leighton Reid, M.D. is a serial entrepreneur and investor who currently serves as a venture partner at Brandon Capital Partners, a global venture capital firm dedicated to biomedical research and capabilities. Leighton is the executive chairman of Global Kinetics Pty Ltd and also serves on the boards of EBR Systems, Glyscend Therapeutics and Okogen. Earlier in his career, Leighton founded and served as managing director and president of the pharma division of Affymax NV. He was also a founding investor, chairman and chief executive officer of Aviron and Avidia. Leighton completed internal medicine training at Duke and the Peter Bent Brigham Hospital, where he held appointments at the Harvard Medical School and School of Public Health. He earned his bachelor’s degree from Rice University and an M.D. from the University of Texas Health Science Center.

Nicole is a venture partner at Arboretum Ventures and serves on the Allay board of directors. Nicole is a longtime biotech investor and company advisor with extensive experience in both public and private investing, as a Partner with Domain Associates, a venture capital firm focused in the life sciences sector. She joined Arboretum as a venture partner in 2023. Nicole currently serves on the board of Esperion Therapeutics and Hinge Bio Inc. Her past board memberships include numerous companies that have entered transactions, including Achillion Pharmaceuticals (Alexion), Calixa Therapeutics (Cubist Pharmaceuticals), Celator Pharmaceuticals (Jazz Pharmaceuticals), Cerexa (Forest Laboratories), Durata Therapeutics (Actavis), Marinus Pharmaceuticals, Onyx Pharmaceuticals, and VentiRx Pharmaceuticals (Celgene). Nicole holds a bachelor’s degree in mathematics and MBA from the University of Rochester.

Christine Allen, Ph.D., is a full professor at the University of Toronto and an internationally recognized leader with more than 170 publications in drug formulation and development. She is a member of the Scientific Leadership Team of the Acceleration Consortium, a strategic initiative at the University of Toronto awarded $200M in funding from the Canada First Research Excellence Fund. She has received numerous awards and is a distinguished fellow of prestigious societies including the American Institute for Medical and Biological Engineering, and the Canadian Academy of Health Sciences. In addition, she is a co-founder and CEO of Intrepid Labs Inc., a company that is accelerating pharmaceutical drug development through integration of AI, automation and advanced computing. She is also a co-founder and board member at Nanovista Inc. Her lab at U of T is deeply engaged in industry partnerships, playing a key role in advancing drugs from early-stage research to clinical trials. Her leadership has been pivotal in several scientific societies, notably as President of the Controlled Release Society and the Canadian Society for Pharmaceutical Sciences. In academia, her roles have included the inaugural Associate Vice-President and Vice Provost Strategic Initiatives and Interim Dean of the Leslie Dan Faculty of Pharmacy. Dr. Allen’s commitment to equity, diversity and inclusion (EDI) goes beyond words. In 2019, she founded the Women in STEAM: Leading and Reading book club to create a community that supports women as they advance in their education and careers. She earned her Ph.D. in Chemistry from McGill University, and her Bachelor of Science from University of Ottawa.

Ron Burch, M.D., Ph.D., currently serves as Chief Medical Officer of Gate Neurosciences, a company developing products to treat psychiatric disorders. He previously served as Chief Medical Officer at Naurex, a clinical-stage biopharmaceutical company developing novel NMDA receptor modulators, and Pacira, an industry leader in non-opioid solutions for pain. Dr. Burch has served as Chairman of Zeneca Pharmaceuticals’ Global CNS Therapeutics Area Team; co-founder and CEO of AlgoRx Pharmaceuticals, a company that successfully developed a number of therapeutic agents for pain management; CEO of Sanguistat, a medical device company that developed devices that inhibited hemorrhage following serious wounds, CEO and Chairman of Biowave Corporation, a medical device company that successfully launched three neurostimulation products to treat chronic, intractable pain and postoperative pain; and Scientific Advisor of Collegium Pharmaceuticals. He also held various managerial positions with Purdue Pharma, including Vice President of Scientific Evaluations and Immunotherapeutics, Medical Director and Project Manager and Medical Safety Officer for several pain development programs. Dr. Burch was a researcher at the National Institutes of Health, performing research involving neuroreceptor regulation with Nobel Laureate Dr. Julius Axelrod. Dr. Burch obtained a Ph.D. in Pharmacology and M.D. from the Medical University of South Carolina. He holds bachelor’s degrees in chemistry and marine biology from the College of Charleston.

Joachim Kohn, Ph.D. is a distinguished professor emeritus at Rutgers University and the founder and principal investigator of the Kohn Lab, a laboratory dedicated to improving health care and quality of life by developing advanced biomedical products for tissue repair, replacement and the delivery of pharmaceutical agents. Dr. Kohn serves as the director of the New Jersey Center for Biomaterials and has been a principal investigator for numerous federally funded research and development programs. His research focuses on the development of new biomaterials, and he has won numerous awards and honors for his breakthrough studies. Dr. Kohn holds a bachelor’s degree from Hebrew University, a Ph.D. from Weizmann Institute, and completed a postdoctoral fellowship in polymeric drug delivery systems at the Massachusetts Institute of Technology.

Lous Lazo Radulovic, Ph.D., M.P.H., is an independent consultant who brings significant experience in pharmacokinetics/drug metabolism and toxicology. Previously, Dr Radulovic worked at Warner-Lamber/Parke-Davis and Pfizer for over 20 years, having held positions of increasing responsibility at both companies. He subsequently started a Michigan office for Fulcrum Pharma Developments, Inc, a multi-national drug development and regulatory consulting company. After leaving Fulcrum, Dr Radulovic founded two independent nonclinical consulting companies, Drug Development Preclinical Services, LLC and Innovative Pharma Consulting, LLC. His expertise spans medical devices, small molecules, and biologics across several therapeutic areas. Dr Radulovic has served on in-licensing/due diligence teams, conducted numerous gap analyses on nonclinical packages, and has extensive regulatory submission experience for CNS drugs and antihyperlipidemics. Dr Radulovic is a retired member of the Society of Toxicology and has served as a member of the editorial board of Drug Metabolism and Disposition. He was also an Adjunct Professor of Toxicology at The University of Michigan and is a graduate of the same institution.

Arthur Tipton, Ph.D., is an independent consultant that aids companies in developing the next generation of drug delivery products. He previously held leadership roles in three drug delivery start-ups and played a key role in each company’s path to a public offering. He was founder and chief executive officer of Brookwood Pharmaceuticals, now part of Evonik. Dr. Tipton holds 43 U.S. patents; his inventive efforts have led to several publications and multiple commercial products. He currently serves as a board member for five organizations and has previous experience on 12 additional boards. His resume also includes induction into the National Academy of Inventors, the College of Fellows for the American Institute for Medical and Biological Engineering and the Controlled Release Society, where he served as president in 2015. Most recently, Dr. Tipton was elected to the National Academy of Engineering in 2021. He holds a Ph.D. in polymer science and engineering from the University of Massachusetts.

Sabry Ayad, M.D., is a Professor of Anesthesiology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, a fellow of the American Society of Anesthesiologists, and the President of the Cleveland Society of Anesthesiologists. In addition, Dr. Ayad is also a senior member of multiple medical societies and committees, such as the American Society of Anesthesiologists (ASA), the American Society of Regional Anesthesia and Pain Medicine (ASRA), Society of Ambulatory Anesthesia (SAMBA), Society of Cardiovascular anesthesiologists (SCA), the Ohio Society of Anesthesiologists (OSA) and the International Anesthesia Research Society (IARS). He has published multiple peer-reviewed manuscripts focused on enhanced recovery after surgery (ERAS), AI and perioperative outcomes, and investigating topics related to postoperative nausea and vomiting, pain management, fluid and hemodynamic management, and anesthetic pharmacology. In 2016, Dr. Ayad was named Fairview Hospital Cleveland Clinic’s Physician of the Year and Safety Champion by the Cleveland Clinic Quality Institute. He earned his M.D. from Alexandria University, M.B.A. from Cleveland State University.

Ron Burch, M.D., Ph.D., currently serves as Chief Medical Officer of Gate Neurosciences, a company developing products to treat psychiatric disorders. He previously served as Chief Medical Officer at Naurex, a clinical-stage biopharmaceutical company developing novel NMDA receptor modulators, and Pacira, an industry leader in non-opioid solutions for pain. Dr. Burch has served as Chairman of Zeneca Pharmaceuticals’ Global CNS Therapeutics Area Team; co-founder and CEO of AlgoRx Pharmaceuticals, a company that successfully developed a number of therapeutic agents for pain management; CEO of Sanguistat, a medical device company that developed devices that inhibited hemorrhage following serious wounds, CEO and Chairman of Biowave Corporation, a medical device company that successfully launched three neurostimulation products to treat chronic, intractable pain and postoperative pain; and Scientific Advisor of Collegium Pharmaceuticals. He also held various managerial positions with Purdue Pharma, including Vice President of Scientific Evaluations and Immunotherapeutics, Medical Director and Project Manager and Medical Safety Officer for several pain development programs. Dr. Burch was a researcher at the National Institutes of Health, performing research involving neuroreceptor regulation with Nobel Laureate Dr. Julius Axelrod. Dr. Burch obtained a Ph.D. in Pharmacology and M.D. from the Medical University of South Carolina. He holds bachelor’s degrees in chemistry and marine biology from the College of Charleston.

David Dalury, M.D., is an Orthopedic Surgeon specializing in total knee replacement, partial knee replacement and total hip replacement. He is a Clinical Professor of Orthopedic Surgery (Emeritus) at the University of Maryland Medicine and has been Chief of Orthopedics at the University of Maryland St. Joseph Medical Center. He is an active member of The Knee Society, the American Association of Orthopedic Surgeons and the American Association of Hip and Knee Surgeons, among other medical associations. His work has been published extensively in peer-reviewed publications. Dr. Dalury is a graduate of Dartmouth Medical School, and he completed his residency and Fellowship in Total Joint Replacement at the Harvard-affiliated hospitals.

Hemant Pandit, FRCS (Orth), D.Phil (Oxon) is a Professor of Orthopaedic Surgery at University of Leeds and at University of Oxford, UK, and currently practices at Chapel Allerton Hospital, C/O Leeds Teaching Hospitals NHS Trust in the UK. Hemant has a high-volume hip and knee arthroplasty practice and is also a clinical academic. In addition, he holds the post of Deputy Dean in the Faculty of Medicine and Health C/O University of Leeds and is Head of School (Leeds Institute of Rheumatic Musculoskeletal Medicine). Dr. Pandit has published 400+ peer-reviewed articles, written 50+ book chapters and leads a multi-disciplinary team of 20+ colleagues. His research interest is focused on translational research across the entire osteoarthritis spectrum aimed at improving patient outcomes and optimizing their management pathways. Hemant’s work on pain relief post knee arthroplasty is well recognized. Hemant is a NIHR Senior Investigator, an elected member of the American Knee Society and European Knee Society and is an MHRA (Medicines and Healthcare Products Regulatory Agency) advisor.

Christine Sang, MD, MPH, FASA is an Associate Professor of Anaesthesia at Harvard Medical School, specializing in both pediatric and adult anesthesiology and acute and chronic pain management. She is the founding director of the Translational Pain Research program at Brigham and Women’s Hospital, which conducts Phases 1a (First-in-Human), 1b/2a (proof-of-concept) and 2b/3 analgesic clinical trials in a variety of pain states and in neurodegeneration. Dr. Sang continues to serve on numerous boards and committees for her institution, leading medical societies, government agencies, publications, nonprofit organizations, and patient advocacy. She is the founding chair of the Medical and Scientific Advisory Committee at United Spinal Association, and served on the board of Praxis Spinal Cord Institute where she was chair of the governance committee. She serves the Department of Health and Human Services as a scientific member of the Interagency Pain Research Coordinating Committee. Dr. Sang obtained her M.D. from the Johns Hopkins University School of Medicine, and her M.P.H. from Harvard T.H. Chan School of Public Health.